Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

A drug discovery platform to identify compounds that inhibit EGFR triple mutants.

Saraon P, Snider J, Kalaidzidis Y, Wybenga-Groot LE, Weiss K, Rai A, Radulovich N, Drecun L, Vučković N, Vučetić A, Wong V, Thériault B, Pham NA, Park JH, Datti A, Wang J, Pathmanathan S, Aboualizadeh F, Lyakisheva A, Yao Z, Wang Y, Joseph B, Aman A, Moran MF, Prakesch M, Poda G, Marcellus R, Uehling D, Samaržija M, Jakopović M, Tsao MS, Shepherd FA, Sacher A, Leighl N, Akhmanova A, Al-Awar R, Zerial M, Stagljar I.

Nat Chem Biol. 2020 Feb 24. doi: 10.1038/s41589-020-0484-2. [Epub ahead of print]

PMID:
32094923
2.

Amplification of a calcium channel subunit CACNG4 increases breast cancer metastasis.

Kanwar N, Carmine-Simmen K, Nair R, Wang C, Moghadas-Jafari S, Blaser H, Tran-Thanh D, Wang D, Wang P, Wang J, Pasculescu A, Datti A, Mak T, Lewis JD, Done SJ.

EBioMedicine. 2020 Feb;52:102646. doi: 10.1016/j.ebiom.2020.102646. Epub 2020 Feb 12.

3.

ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway.

Moskal N, Riccio V, Bashkurov M, Taddese R, Datti A, Lewis PN, Angus McQuibban G.

Nat Commun. 2020 Jan 3;11(1):88. doi: 10.1038/s41467-019-13781-3.

4.

Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.

Black M, Ghasemi F, Sun RX, Stecho W, Datti A, Meens J, Pinto N, Ruicci KM, Khan MI, Han MW, Shaikh M, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Howlett CJ, Mymryk JS, Ailles L, Boutros PC, Barrett JW, Nichols AC.

Oral Oncol. 2020 Feb;101:104529. doi: 10.1016/j.oraloncology.2019.104529. Epub 2019 Dec 19.

PMID:
31864959
5.

Selenium maintains cytosolic Ca2+ homeostasis and preserves germination rates of maize pollen under H2O2-induced oxidative stress.

Del Pino AM, Guiducci M, D'Amato R, Di Michele A, Tosti G, Datti A, Palmerini CA.

Sci Rep. 2019 Sep 18;9(1):13502. doi: 10.1038/s41598-019-49760-3.

6.

Cell-based high-throughput screen for small molecule inhibitors of Bax translocation.

Hui KK, Dojo Soeandy C, Chang S, Vizeacoumar FS, Sun T, Datti A, Henderson JT.

J Cell Mol Med. 2019 Mar;23(3):1784-1797. doi: 10.1111/jcmm.14076. Epub 2018 Dec 13.

7.

Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.

Pinto N, Prokopec SD, Vizeacoumar F, Searle K, Lowerison M, Ruicci KM, Yoo J, Fung K, MacNeil D, Lacefield JC, Leong HS, Mymryk JS, Barrett JW, Datti A, Boutros PC, Nichols AC.

PLoS One. 2018 Nov 12;13(11):e0207152. doi: 10.1371/journal.pone.0207152. eCollection 2018.

8.

COX inhibitors and bone: A safer impact on osteoblasts by NO-releasing NSAIDs.

Aisa MC, Datti A, Orlacchio A, Di Renzo GC.

Life Sci. 2018 Sep 1;208:10-19. doi: 10.1016/j.lfs.2018.07.011. Epub 2018 Jul 7.

PMID:
29990484
9.

High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.

Ghasemi F, Black M, Sun RX, Vizeacoumar F, Pinto N, Ruicci KM, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Mymryk JS, Ailles LA, Datti A, Barrett JW, Boutros PC, Nichols AC.

Oncotarget. 2018 May 25;9(40):26064-26071. doi: 10.18632/oncotarget.25436. eCollection 2018 May 25.

10.

Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.

Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, Jones R, Ju Y, Pellecchia G, Jiang Z, Palmerini CA, Ben-David Y, Egan SE, Woodgett JR, Bader GD, Datti A, Zacksenhaus E.

Cell Rep. 2018 Apr 3;23(1):112-126. doi: 10.1016/j.celrep.2018.03.039.

11.

Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer.

Ghasemi F, Black M, Vizeacoumar F, Pinto N, Ruicci KM, Le CCSH, Lowerison MR, Leong HS, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Mymryk JS, Boutros PC, Datti A, Barrett JW, Nichols AC.

Oncotarget. 2017 Apr 20;8(42):71512-71519. doi: 10.18632/oncotarget.17292. eCollection 2017 Sep 22.

12.

Multilayered Control of Alternative Splicing Regulatory Networks by Transcription Factors.

Han H, Braunschweig U, Gonatopoulos-Pournatzis T, Weatheritt RJ, Hirsch CL, Ha KCH, Radovani E, Nabeel-Shah S, Sterne-Weiler T, Wang J, O'Hanlon D, Pan Q, Ray D, Zheng H, Vizeacoumar F, Datti A, Magomedova L, Cummins CL, Hughes TR, Greenblatt JF, Wrana JL, Moffat J, Blencowe BJ.

Mol Cell. 2017 Feb 2;65(3):539-553.e7. doi: 10.1016/j.molcel.2017.01.011.

13.

Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.

Rotin LE, MacLean N, Aman A, Gronda M, Lin FH, Hurren R, Wang X, Wrana JL, Datti A, Al-Awar R, Minden MD, Schimmer AD.

Haematologica. 2016 Nov;101(11):e449-e453. Epub 2016 Sep 1. No abstract available.

14.

Excess Polθ functions in response to replicative stress in homologous recombination-proficient cancer cells.

Goullet de Rugy T, Bashkurov M, Datti A, Betous R, Guitton-Sert L, Cazaux C, Durocher D, Hoffmann JS.

Biol Open. 2016 Oct 15;5(10):1485-1492. doi: 10.1242/bio.018028.

15.

RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, Chung PE, Pellecchia G, Fell VL, Bae S, Muthuswamy L, Datti A, Egan SE, Jiang Z, Leone G, Bader GD, Schimmer A, Zacksenhaus E.

J Clin Invest. 2016 Oct 3;126(10):3739-3757. doi: 10.1172/JCI81568. Epub 2016 Aug 29.

16.

The RNF146 and tankyrase pathway maintains the junctional Crumbs complex through regulation of angiomotin.

Campbell CI, Samavarchi-Tehrani P, Barrios-Rodiles M, Datti A, Gingras AC, Wrana JL.

J Cell Sci. 2016 Sep 15;129(18):3396-411. doi: 10.1242/jcs.188417. Epub 2016 Aug 12.

17.

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, Wrana JL, Easaw JC, Luchman A, Weiss S, Cairncross JG, Kaplan DR, Robbins SM, Senger DL.

Clin Cancer Res. 2016 Aug 1;22(15):3860-75. doi: 10.1158/1078-0432.CCR-15-1798. Epub 2016 Mar 22.

18.

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.

Babichev Y, Kabaroff L, Datti A, Uehling D, Isaac M, Al-Awar R, Prakesch M, Sun RX, Boutros PC, Venier R, Dickson BC, Gladdy RA.

J Transl Med. 2016 Mar 8;14:67. doi: 10.1186/s12967-016-0814-z.

19.

High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor.

Zhang L, Yang Z, Granieri L, Pasculescu A, Datti A, Asa SL, Xu Z, Ezzat S.

Oncotarget. 2016 Apr 12;7(15):19948-59. doi: 10.18632/oncotarget.7890.

20.

Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.

Wang S, Liu JC, Kim D, Datti A, Zacksenhaus E.

Breast Cancer Res. 2016 Jan 19;18(1):9. doi: 10.1186/s13058-015-0668-y.

21.

Identification of Drugs that Regulate Dermal Stem Cells and Enhance Skin Repair.

Naska S, Yuzwa SA, Johnston AP, Paul S, Smith KM, Paris M, Sefton MV, Datti A, Miller FD, Kaplan DR.

Stem Cell Reports. 2016 Jan 12;6(1):74-84. doi: 10.1016/j.stemcr.2015.12.002. Epub 2015 Dec 24.

22.

Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.

Rotin LE, Gronda M, MacLean N, Hurren R, Wang X, Lin FH, Wrana J, Datti A, Barber DL, Minden MD, Slassi M, Schimmer AD.

Oncotarget. 2016 Jan 19;7(3):2765-79. doi: 10.18632/oncotarget.6409.

23.

Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.

Srivastava G, Matta A, Fu G, Somasundaram RT, Datti A, Walfish PG, Ralhan R.

Mol Oncol. 2015 Oct;9(8):1720-35. doi: 10.1016/j.molonc.2015.05.005. Epub 2015 May 21.

24.

Corrigendum: Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.

Hirsch CL, Akdemir ZC, Wang L, Jayakumaran G, Trcka D, Weiss A, Hernandez JJ, Pan Q, Han H, Xu X, Xia Z, Salinger AP, Wilson M, Vizeacoumar F, Datti A, Li W, Cooney AJ, Barton MC, Blencowe BJ, Wrana JL, Dent SY.

Genes Dev. 2015 Jun 15;29(12):1341. doi: 10.1101/gad.266601.115. No abstract available.

25.

Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death.

Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R, Wang XM, Gronda M, Boyaci E, Bojko B, Minden M, Sriskanthadevan S, Datti A, Wrana JL, Edginton A, Pawliszyn J, Joseph JW, Quadrilatero J, Schimmer AD, Spagnuolo PA.

Cancer Res. 2015 Jun 15;75(12):2478-88. doi: 10.1158/0008-5472.CAN-14-2676.

26.

Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.

Hirsch CL, Coban Akdemir Z, Wang L, Jayakumaran G, Trcka D, Weiss A, Hernandez JJ, Pan Q, Han H, Xu X, Xia Z, Salinger AP, Wilson M, Vizeacoumar F, Datti A, Li W, Cooney AJ, Barton MC, Blencowe BJ, Wrana JL, Dent SY.

Genes Dev. 2015 Apr 15;29(8):803-16. doi: 10.1101/gad.255109.114. Epub 2015 Apr 15. Erratum in: Genes Dev. 2015 Jun 15;29(12):1341.

27.

Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.

Bernard D, Gebbia M, Prabha S, Gronda M, MacLean N, Wang X, Hurren R, Sukhai MA, Cho EE, Manolson MF, Datti A, Wrana J, Minden MD, Al-Awar R, Aman A, Nislow C, Giaever G, Schimmer AD.

Apoptosis. 2015 Jul;20(7):948-59. doi: 10.1007/s10495-015-1123-3.

PMID:
25832785
28.

Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.

Liu JC, Voisin V, Wang S, Wang DY, Jones RA, Datti A, Uehling D, Al-awar R, Egan SE, Bader GD, Tsao M, Mak TW, Zacksenhaus E.

EMBO Mol Med. 2014 Dec;6(12):1542-60. doi: 10.15252/emmm.201404402.

29.

A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening.

Jeon J, Nim S, Teyra J, Datti A, Wrana JL, Sidhu SS, Moffat J, Kim PM.

Genome Med. 2014 Jul 30;6(7):57. doi: 10.1186/s13073-014-0057-7. eCollection 2014.

30.

RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.

Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A, Zacksenhaus E.

PLoS One. 2013 Nov 12;8(11):e78641. doi: 10.1371/journal.pone.0078641. eCollection 2013.

31.

A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.

Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH, Sayad A, Mero P, Lawo S, Tanaka H, Brown KR, Baryshnikova A, Mak AB, Fedyshyn Y, Wang Y, Brito GC, Kasimer D, Makhnevych T, Ketela T, Datti A, Babu M, Emili A, Pelletier L, Wrana J, Wainberg Z, Kim PM, Rottapel R, O'Brien CA, Andrews B, Boone C, Moffat J.

Mol Syst Biol. 2013 Oct 8;9:696. doi: 10.1038/msb.2013.54.

32.

High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.

Robinson TJ, Pai M, Liu JC, Vizeacoumar F, Sun T, Egan SE, Datti A, Huang J, Zacksenhaus E.

Cell Cycle. 2013 Sep 15;12(18):3013-24. doi: 10.4161/cc.26063. Epub 2013 Aug 12.

33.

MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.

Goswami RS, Atenafu EG, Xuan Y, Waldron L, Reis PP, Sun T, Datti A, Xu W, Kuruvilla J, Good DJ, Lai R, Church AJ, Lam WS, Baetz T, Lebrun DP, Sehn LH, Farinha P, Jurisica I, Bailey DJ, Gascoyne RD, Crump M, Kamel-Reid S.

J Clin Oncol. 2013 Aug 10;31(23):2903-11. doi: 10.1200/JCO.2012.45.3050. Epub 2013 Jul 8.

PMID:
23835716
34.

Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients.

Martino S, Montesano S, di Girolamo I, Tiribuzi R, Di Gregorio M, Orlacchio A, Datti A, Calabresi P, Sarchielli P, Orlacchio A.

Mult Scler. 2013 Oct;19(11):1443-53. doi: 10.1177/1352458513477230. Epub 2013 Feb 25.

PMID:
23439581
35.

High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer.

Izrailit J, Berman HK, Datti A, Wrana JL, Reedijk M.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1714-9. doi: 10.1073/pnas.1214014110. Epub 2013 Jan 14.

36.

Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity.

Spagnuolo PA, Hurren R, Gronda M, MacLean N, Datti A, Basheer A, Lin FH, Wang X, Wrana J, Schimmer AD.

Leukemia. 2013 Jun;27(6):1236-44. doi: 10.1038/leu.2013.9. Epub 2013 Jan 15.

PMID:
23318959
37.

Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.

Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, Sun H, Wang X, Skrtic M, Seneviratne A, Cusimano M, Jhas B, Gronda M, MacLean N, Cho EE, Spagnuolo PA, Sharmeen S, Gebbia M, Urbanus M, Eppert K, Dissanayake D, Jonet A, Dassonville-Klimpt A, Li X, Datti A, Ohashi PS, Wrana J, Rogers I, Sonnet P, Ellis WY, Corey SJ, Eaves C, Minden MD, Wang JC, Dick JE, Nislow C, Giaever G, Schimmer AD.

J Clin Invest. 2013 Jan;123(1):315-28. doi: 10.1172/JCI64180. Epub 2012 Dec 3.

38.

Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.

Crasto GJ, Kartner N, Yao Y, Li K, Bullock L, Datti A, Manolson MF.

J Cell Biochem. 2013 Apr;114(4):929-41. doi: 10.1002/jcb.24434.

PMID:
23129004
39.

Drug-mediated inhibition of Fli-1 for the treatment of leukemia.

Li YJ, Zhao X, Vecchiarelli-Federico LM, Li Y, Datti A, Cheng Y, Ben-David Y.

Blood Cancer J. 2012 Jan;2(1):e54. doi: 10.1038/bcj.2011.52. Epub 2012 Jan 27.

40.

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JLY, van Dyk D, Fedyshyn B, Luhova M, Brito GC, Vizeacoumar FJ, Vizeacoumar FS, Datti A, Kasimer D, Buzina A, Mero P, Misquitta C, Normand J, Haider M, Ketela T, Wrana JL, Rottapel R, Neel BG, Moffat J.

Cancer Discov. 2012 Feb;2(2):172-189. doi: 10.1158/2159-8290.CD-11-0224. Epub 2011 Dec 29.

41.

A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside.

McDermott SP, Eppert K, Notta F, Isaac M, Datti A, Al-Awar R, Wrana J, Minden MD, Dick JE.

Blood. 2012 Feb 2;119(5):1200-7. doi: 10.1182/blood-2011-01-330019. Epub 2011 Dec 9.

PMID:
22160482
42.

Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

Skrtić M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, Spagnuolo P, Rutledge AC, Datti A, Ketela T, Moffat J, Robinson BH, Cameron JH, Wrana J, Eaves CJ, Minden MD, Wang JC, Dick JE, Humphries K, Nislow C, Giaever G, Schimmer AD.

Cancer Cell. 2011 Nov 15;20(5):674-88. doi: 10.1016/j.ccr.2011.10.015.

43.

PhenoM: a database of morphological phenotypes caused by mutation of essential genes in Saccharomyces cerevisiae.

Jin K, Li J, Vizeacoumar FS, Li Z, Min R, Zamparo L, Vizeacoumar FJ, Datti A, Andrews B, Boone C, Zhang Z.

Nucleic Acids Res. 2012 Jan;40(Database issue):D687-94. doi: 10.1093/nar/gkr827. Epub 2011 Oct 18.

44.

Activators of cylindrical proteases as antimicrobials: identification and development of small molecule activators of ClpP protease.

Leung E, Datti A, Cossette M, Goodreid J, McCaw SE, Mah M, Nakhamchik A, Ogata K, El Bakkouri M, Cheng YQ, Wodak SJ, Eger BT, Pai EF, Liu J, Gray-Owen S, Batey RA, Houry WA.

Chem Biol. 2011 Sep 23;18(9):1167-78. doi: 10.1016/j.chembiol.2011.07.023.

45.

Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks.

Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, Diamandis EP.

Mol Cancer Ther. 2011 Nov;10(11):2083-93. doi: 10.1158/1535-7163.MCT-11-0421. Epub 2011 Aug 22.

46.

Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.

Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5605-9. doi: 10.1016/j.bmcl.2011.06.056. Epub 2011 Jun 30.

47.

Systematic exploration of essential yeast gene function with temperature-sensitive mutants.

Li Z, Vizeacoumar FJ, Bahr S, Li J, Warringer J, Vizeacoumar FS, Min R, Vandersluis B, Bellay J, Devit M, Fleming JA, Stephens A, Haase J, Lin ZY, Baryshnikova A, Lu H, Yan Z, Jin K, Barker S, Datti A, Giaever G, Nislow C, Bulawa C, Myers CL, Costanzo M, Gingras AC, Zhang Z, Blomberg A, Bloom K, Andrews B, Boone C.

Nat Biotechnol. 2011 Apr;29(4):361-7. doi: 10.1038/nbt.1832. Epub 2011 Mar 27.

48.

Inhibition of SREBP1 sensitizes cells to death ligands.

Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, Moffat J, Wrana JL, Schimmer AD.

Oncotarget. 2011 Mar;2(3):186-96.

49.

Lysosomal β-galactosidase and β-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus.

Tiribuzi R, Orlacchio A, Crispoltoni L, Maiotti M, Zampolini M, De Angeliz M, Mecocci P, Cecchetti R, Bernardi G, Datti A, Martino S, Orlacchio A.

J Alzheimers Dis. 2011;24(4):785-97. doi: 10.3233/JAD-2011-100525.

PMID:
21321400
50.

Coordinated involvement of cathepsins S, D and cystatin C in the commitment of hematopoietic stem cells to dendritic cells.

Martino S, Tiribuzi R, Ciraci E, Makrypidi G, D'Angelo F, di Girolamo I, Gritti A, de Angelis GM, Papaccio G, Sampaolesi M, Berardi AC, Datti A, Orlacchio A.

Int J Biochem Cell Biol. 2011 May;43(5):775-83. doi: 10.1016/j.biocel.2011.02.001. Epub 2011 Feb 17.

PMID:
21315176

Supplemental Content

Support Center